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A growing number of genetic susceptibility factors have been identified for Parkinson’s disease (PD). 
The combination of inherited risk variants is likely to affect not only risk of developing PD but also its 
clinical course. Variants in the GBA gene are particularly common, being found in approximately 5 to 
10% of patients, and they lead to more rapid disease progression1. However, the effect of concomitant 
genetic risk factors on disease course in GBA-PD is not known. 
The aggregation of α-synuclein, encoded by the SNCA gene, is central to the pathogenesis of PD. The 
SNCA rs356219 A/G polymorphism alters the risk of developing PD, with homozygotes for guanine 
(G/G) having an increased risk compared to carriers of an adenine (G/A or A/A) at this locus2. The 
relationship between glucocerebrosidase (the enzyme encoded by the GBA gene) and α-synuclein is 
complex. These proteins have been shown to interact directly in vitro, as well as to influence the 
intracellular levels and processing of each other, potentially in a bidirectional feedback loop3 4. 
Interestingly, a recent genome-wide association study found that the presence of this SNCA 
polymorphism was associated with an increased likelihood of developing PD in GBA mutation-
carriers5. We therefore hypothesised that the presence of the SNCA rs356219 polymorphism would 
accelerate the clinical course of GBA variant-associated PD. Here we report on the effect of this SNCA 
polymorphism on clinical outcomes within the GBA-PD population. 
Longitudinal data from GBA-variant carriers was analysed from the community-based “Cambridgeshire 
Incidence of Parkinson’s disease from General Practice to Neurologist” (CamPaIGN) cohort (n=142)6. 
This study was approved by the local ethics committee and written informed consent was obtained from 
all subjects. Newly diagnosed patients were followed up with assessments every 2 years for up to 18 
years. Time to development of dementia (defined as Mini-Mental State Examination (MMSE) score of 
24 or less, with fulfilment of Diagnostic and Statistical Manual of Mental Disorders IV (DSM-IV) 
criteria), progression to postural instability (Hoehn and Yahr stage three (HY3)), and death were 
determined. 
Sequencing of the GBA gene was carried out in 114 patients in the CamPaIGN cohort, as described 
here7. A further 16 patients underwent targeted genetic screening for common GBA variants using the 
Illumina Multi-Ethnic Genotyping Array (MEGA) ChIP. Genetic analysis of the SNCA rs356219 
polymorphism had also been previously performed in 124 patients from the cohort2. GBA variants were 
identified in 20 patients, which were included in survival analyses. Of these, 7 carried the high-risk 
(G/G) SNCA genotype, with 13 carrying low-risk (G/A or A/A) genotypes. There were no differences 
in age at diagnosis nor in baseline assessments including total and part III Unified Parkinson’s Disease 
Rating Scale scores, Hoehn and Yahr scores, MMSE scores, or levodopa equivalent doses between 
these SNCA genotype groups. All carriers of the G/G genotype were male, compared to 53.8% in the 
low-risk group (p=0.03) (supplementary table 1). 
Survival analyses for the aforementioned outcome measures were performed, with statistical 
significance determined using log-rank tests. P-values were adjusted for multiple comparisons using 
the Bonferroni method. Amongst carriers of GBA variants, there were no differences between the high- 
and low-risk SNCA groups for time to dementia (p=0.29, adjusted p=0.86) or death (p=0.43, adjusted 
p=1.28) (figure 1A and B). Progression to HY3 however, was significantly faster in the G/G SNCA 
group (p=0.02, adjusted p=0.07), with mean time to development of postural instability 2.0 years (95% 
confidence interval 1.3-2.7) compared to 4.9 years (95% confidence interval 2.5-7.3) in A carriers 
(figure 1C). All G/G carriers reached HY3 within three years of diagnosis. 
To account for potential confounders, time to HY3 was also compared using a Cox regression model 
controlling for sex and age at diagnosis. The G/G SNCA genotype was associated with a hazard ratio 
for progression to HY3 of 3.8 (95% confidence interval 0.9-16.1) p=0.07, adjusted p=0.21) when 
controlling for these confounders. Because all of the SNCA G/G carriers were male, we also performed 
a survival analysis in which only male subjects were included, to further control for sex as a potential 
confounder. An increased risk of progression to HY3 was again observed in G/G carriers in comparison 
to A carriers (p=0.036, adjusted p=0.11; supplementary figure 1). SNCA genotype had no effect on 
progression to HY3 in non-carriers of GBA variants (n=85) in the CamPaIGN cohort (p=0.88, adjusted 
p=2.65; supplementary figure 2). 
This cohort contained four patients with the non-coding c. 762 – 18 T>A variant (supplementary table 
2). Whilst this has been reported to be a potential risk factor for PD8, its importance is not clear. We 
therefore also performed analysis after exclusion of these patients, and found that progression to HY3 
was greater in the G/G carrier group, with a hazard ratio of 5.3 (95% confidence interval 1.1-26.2; 
p=0.041, adjusted p=0.12). 
To our knowledge, no previous studies have investigated the influence of concomitant genetic risk 
factors on the progression of GBA-PD. Here we report that the SNCA rs356219 polymorphism 
significantly affects motor progression in GBA-PD, with the G/G genotype associated with a 
particularly aggressive disease course. This effect was not observed in PD patients without GBA 
variants, suggesting that it was relatively specific to GBA-PD.  
This new study therefore raises the interesting possibility that GBA variants and the G/G SNCA 
rs356219 polymorphism act synergistically to accelerate pathology and clinical progression in PD. GBA 
mutations are thought to increase the risk of PD predominantly through perturbations in the lysosome-
autophagy system – a system important in α-synuclein clearance. Furthermore, glucocerebrosidase and 
α-synuclein have been shown to interact directly in vitro, and to co-exist in Lewy bodies of PD patients, 
with a greater proportion of Lewy bodies containing glucocerebrosidase in patients with GBA mutations 
compared to those in PD patients not carrying a GBA variant4 9. It has been speculated that mutant 
GCase potentiates the aggregation of α-synuclein, and it is therefore feasible that SNCA variants such 
as the rs356219 polymorphism alter the degree to which GBA variants predispose to PD pathology and 
disease progression. It has also been suggested that α-synuclein impedes the transit of 
glucocerebrosidase from the endoplasmic reticulum to the lysosome, further supporting the idea that 
the relationship between these two proteins is directly important in the pathogenesis of GBA-PD3. The 
proposed synergistic interaction between variants in the GBA gene and SNCA gene therefore could also 
potentially be explained by differences in the degree to which α-synuclein impairs normal GCase 
processing associated with specific SNCA variants.  
We acknowledge that our sample size is small, but these preliminary observations raise the possibility 
that GBA variants and the G/G SNCA rs356219 polymorphism synergistically alter motor progression 
in PD. In this study we have considered the time from diagnosis to the development of important clinical 
milestones in PD. The time to diagnosis may vary between patients, so it should be recognised that this 
does not necessarily reflect disease duration. Time from disease onset to the development of clinical 
milestones may be more representative of disease duration but onset is very difficult to ascertain 
accurately, given that many patients experience prodromal symptoms that are not initially attributed to 
PD. 
There is a degree of genotype-phenotype correlation in GBA-PD, with severe mutations accelerating 
disease course to a greater extent than less severe variants10. However, because our sample size was 
small, it was not possible to stratify the GBA-PD patients into those with non-severe and severe GBA 
variants, so our GBA-PD population was genetically heterogeneous (supplementary table 2).  Mean age 
at diagnosis was approximately five years later in G/G carriers which may potentially have contributed 
to their accelerated disease course. However, there were no differences in time to dementia or death, 
and when age at diagnosis was accounted for in the Cox regression model, the accelerated progression 
to HY3 persisted. Another limitation of our study is that all subjects in the G/G group were male, and 
though this was accounted for in the Cox regression model, it would be important to investigate the 
relationship between these two genetic risk factors in a large cohort, to reduce the effect of such 
confounders, and to allow for the stratification of G/G carriers into those with severe and those with 
mild GBA variants. 
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 Figure 1 – Survival analyses in GBA1-PD patients comparing those with high- and low-risk variants 
in the SNCA rs356219 polymorphism. Kaplan-Meier curves for time to dementia (A), death (B) and 
postural instability (C). Abbreviations: H&Y3 = Hoehn and Yahr stage three  
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Supplementary Information 
 
 G/G G/A and A/A P-value 
Number 7 13 - 
Gender M:F 7:0 7:6 0.032 
Age at diagnosis (SD) 72.4 years (10.3) 75.5 years (9.3) 0.297 
Years in education (SD) 9.7 years (1.1) 10.6 years (2.8) 0.428 
Total UPDRS at baseline (SD) 48.8 (15.7) 44.1 (14.0) 0.5 
Motor UPDRS at baseline (SD) 21.9 (13.0) 30.8 (9.9) 0.825 
Hoehn & Yahr stage at baseline (SD) 2.1 (0.6) 2.3 (0.6) 0.445 
MMSE at baseline (SD) 27.6 (1.5) 27.2 (1.9) 0.624 
BDI at baseline (SD) 7.9 (5.5) 7.4 (5.6) 0.858 
Baseline levodopa equivalent dose (SD) 188.6 mg (201.0) 185.4mg (213.3) 0.974 
Supplementary Table 1 – Patient demographics. 
  
Patient Number GBA Variant SNCA Genotype 
1 E326K G/G 
2 T369M G/G 
3 N370S* G/G 
4 c. 762 - 18 T>A G/G 
5 L444P* G/G 
6 T369M G/G 
7 c. 762 - 18 T>A G/G 
8 T369M A/G 
9 c. 762 - 18 T>A A/G 
10 E326K A/G 
11 T369M A/G 
12 E326K A/G 
13 T369M A/G 
14 R257Q* A/G 
15 E326K A/A 
16 R48W* A/A 
17 L119L A/A 
18 c. 762 - 18 T>A A/A 
19 E326K A/A 
20 N462K* A/A 
Supplementary Table 2 – GBA Variants and SNCA rs356219 carrier status in all subjects. 
Asterixes indicate variants previously associated with Gaucher disease. 
  
 Supplementary figure 1 – Survival analyses in GBA1-PD patients comparing those with 
high- and low-risk variants in the SNCA rs356219 polymorphism. Kaplan-Meier curves 
for time to postural instability. To control for sex as a potential confounder, female patients 
were excluded, as all subjects in the SNCA G/G group were male. Abbreviations: HY3 = Hoehn 
and Yahr stage three. 
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 Supplementary Figure 2 – Time to postural instability in PD patients without GBA 
variants, comparing those with high- and low-risk variants in the SNCA rs356219 
polymorphism. Kaplan-Meier curve for time to postural instability in patients, comparing 
those carrying the G/G SNCA rs356219 variant to A carriers at this locus. Abbreviations: 
H&Y3 = Hoehn and Yahr stage three.  
 
 
 
 
